Analystreport

SpringWorks Therapeutics (NASDAQ: SWTX) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating and a $37.00 price target on the stock.

SpringWorks Therapeutics, Inc. - common stock  (SWTX) 
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm Check Earnings Report